biostudies-literatureMapuskar KANCI NIH HHS102599https://www.ebi.ac.uk/biostudies/studies/S-EPMC9852651biostudies-literatureUnknown60Head and neck squamous cell carcinoma (HNSCC) patients treated with high-dose cisplatin concurrently with radiotherapy (hdCis-RT) commonly suffer kidney injury leading to acute and chronic kidney disease (AKD and CKD, respectively). We conducted a retrospective analysis of renal function and kidney injury-related plasma biomarkers in a subset of HNSCC subjects receiving hdCis-RT in a double-blinded, placebo-controlled clinical trial (NCT02508389) evaluating the superoxide dismutase mimetic, avasopasem manganese (AVA), an investigational new drug. We found that 90 mg AVA treatment prevented a significant reduction in estimated glomerular filtration rate (eGFR) three months as well as six and twelve months after treatment compared to 30 mg AVA and placebo. Moreover, AVA treatment may have alRedox biologyAvasopasem manganese (GC4419) protects against cisplatin-induced chronic kidney disease: An exploratory analysis of renal metrics from a randomized phase 2b clinical trial in head and neck cancer patients.PMC9852651T32 CA078586R50 CA243693P01 CA217797Vasquez Martinez GSaunders DPSteinbach EJHolmlund JTJetton JGCl HMonga VBodeker KLAnderson CMBeardsley RASpitz DRZepeda-Orozco DAllen BGDunlap NEPearce ADavidson SBuatti JMPetronek MSPitre LFurqan MMapuskar KALee CMMott SLFairbanks RPulliam CFfalseAvasopasem manganese (GC4419) protects against cisplatin-induced chronic kidney disease: An exploratory analysis of renal metrics from a randomized phase 2b clinical trial in head and neck cancer patients.Head and neck squamous cell carcinoma (HNSCC) patients treated with high-dose cisplatin concurrently with radiotherapy (hdCis-RT) commonly suffer kidney injury leading to acute and chronic kidney disease (AKD and CKD, respectively). We conducted a retrospective analysis of renal function and kidney injury-related plasma biomarkers in a subset of HNSCC subjects receiving hdCis-RT in a double-blinded, placebo-controlled clinical trial (NCT02508389) evaluating the superoxide dismutase mimetic, avasopasem manganese (AVA), an investigational new drug. We found that 90 mg AVA treatment prevented a significant reduction in estimated glomerular filtration rate (eGFR) three months as well as six and twelve months after treatment compared to 30 mg AVA and placebo. Moreover, AVA treatment may have al2023-01-01T00:00:00Z2023 Apr2026-07-14T16:58:44.11Z2024-11-19T19:09:18.584ZS-EPMC98526513664072510.1016/j.redox.2022.102599